Background
==========

Radical open gastrectomy is one of the major upper abdominal surgeries that have been reported to cause acute postoperative pain [@B1]. Moreover, the severity of pain is higher especially in this upper-abdominal surgery, which can lead to the impairment of the respiratory effort due to the restriction of the movement of the thoracic cage and abdomen, as well as the decreased respiratory capacity [@B2], [@B3]. Such changes have a negative impact on the course of postoperative recovery [@B4].

Conventionally, pain after open gastrectomy has been controlled with thoracic epidural patient-controlled analgesia (E-PCA) or intravenous PCA (IV-PCA) [@B1], [@B4]. Thoracic E-PCA has an excellent effect in controlling postoperative pain, when properly positioned [@B1], [@B5]-[@B7]. However, as it is a relatively invasive technique, its application is limited by specific contraindications such as infection or bleeding tendency, and there is a possibility of malpositioning of the catheter in the spinal nerve roots leading to severe postoperative neurologic deficits due to ischemia of the sensory and motor nerves [@B5], [@B7]-[@B10]. Therefore, despite its potential benefits, the clinical use of E-PCA may have even declined because of these types of complications [@B1], [@B11].

In case of IV-PCA, higher doses of opioids are required to control postoperative pain effectively; however, this often leads to the discontinuation of IV-PCA because of persistent adverse effects such as nausea, vomiting, and pruritus [@B1], [@B12], [@B13].

Dexmedetomidine is well recognized as an extremely preferential α2-receptor agonist that has sedative and analgesic effects without unfavorable respiratory suppression [@B14]-[@B16]. Previous studies have reported that dexmedetomidine administration during surgery could reduce the amounts of opioids and analgesics used after surgery [@B17]-[@B20]. Furthermore, current studies on the combination of dexmedetomidine with various opioid-based IV-PCA techniques have demonstrated that this combination treatment could help provide better analgesia and opioid-sparing effects without any remarkable unfavorable effects [@B21]-[@B24].

Hence, in this prospective, randomized clinical trial, we investigated the effects of dexmedetomidine in combination with fentanyl-based IV-PCA on pain attenuation in patients undergoing open gastrectomy in comparison with conventional thoracic E-PCA and IV-PCA.

Materials and Methods
=====================

Study population
----------------

This investigation was approved from the Institutional Review Board and Hospital Research Ethics Committee of Severance Hospital (Yonsei University Health System in Seoul, Korea; IRB protocol No. 4-2014-0883), and consequently registered at <http://clinicaltrials.gov> (registration No. NCT02325882). After acquiring written informed consent from all patients, 171 patients with stomach cancer, of age 20 to 65 years and American Society of Anesthesiologists physical status I/II, who were planned to undergo elective conventional open gastrectomy, were enrolled between July, 2015 and March, 2016. The exclusion criteria were as follows: refusal of PCA application; histories of abdominal surgery; prior cardiac disease including unstable angina, congestive heart failure, uncontrolled hypertension; concomitant coagulopathy; presence of vertebral deformity or disease; concomitant pulmonary, renal, or hepatic disease; any contraindication to epidural catheterization; any allergy or hypersensitivity to fentanyl, α~2~-adrenergic agonists, or local anesthetics; use of any type of chronic pain killer or current opioid; cognitive, neurological, or psychiatric impairment; and incapability to report the pain intensity on the pain scale. All enrolled patients were educated on how to express the intensity of pain by using the numerical rating scale (NRS; 0, no pain, and 10, worst pain possible) [@B25], and on how to use the PCA machine in the preanesthetic room.

Randomization and Perioperative Protocol
----------------------------------------

The assignments of the patients were performed randomly into one of 3 groups (1:1:1) according to preset random numbers by using a computer-generated table (<http://www.random.org>) with no dividing blocks and stratification: conventional thoracic E-PCA (E-PCA group, n = 57), dexmedetomidine in combination with fentanyl-based IV-PCA (dIV-PCA group, n = 57), or fentanyl-based IV-PCA only (IV-PCA group, n = 57).

In the E-PCA group, the procedure for epidural catheter insertion was completed before the induction of general anesthesia. After standard monitoring, a single investigator performed the epidural catheterization at the level of T7-8 or T8-9 by using a 17-gauge Tuohy needle, and a catheter was advanced 5 cm into the epidural space. Intravascular or subarachnoid placement of the epidural catheter was excluded by checking the absence of aspirated blood or cerebrospinal fluid. Furthermore, intrathecal delivery of the local anesthetic was ruled out by confirming that no rapid onset of neuroaxial block was developed after the administration of 3 mL of 1% lidocaine. Upon the initiation of peritoneal closure, the PCA machine (Accumate 1100^®^; Woo Young Medical Co., Ltd., Seoul, Korea) was started after 5 mL of 0.15% ropivacaine was administered via the epidural catheter. The PCA regimen was a mixture of 0.15% ropivacaine and 3 µg/mL of fentanyl in 0.9% normal saline solution with a total volume of 250 mL. All PCA machines for the 3 groups were programmed to deliver at the rate of 5 mL/h with a 0.5 mL per demand allowed every 15-minute lockout time.

In the IV-PCA group, after 1 µg/kg of fentanyl was administered intravenously at the start of peritoneal closure, PCA machine was applied intravenously, which consisted 15 µg/kg of fentanyl and 0.3 mg of ramosetron (Nasea, Astellas, Tokuo, Japan), mixed with 0.9% normal saline solution to a total volume of 250 mL. Thus, in the IV-PCA group, fentanyl was infused basally at a rate of 0.3 µg/kg/ h with a bolus dose of 0.03 µg/kg and a lockout time of 15-min.

In the dIV-PCA group, dexmedetomidine (100 μg/mL at 2 mL/vial; Hospira Worldwide, Seoul, Korea) was infused continuously at a rate of 0.1 µg/kg/ h from anesthetic induction until the start of peritoneal closure. Subsequently, the PCA, containing dexmedetomidine in addition to the fentanyl and ramosetron like in the IV-PCA group, was applied intravenously. Thus, in the dIV-PCA group, the background infusion rate of dexmedetomidine was 0.07µg/kg/ h with a bolus dose of 0.007 µg/kg, and that of fentanyl was 0.3µg/kg/ h with a bolus dose of 0.03 µg/kg allowed every 15-min lockout time. In all three groups, the agents for PCA and the study drug were prepared by an investigator who was not involved in the assessment of postoperative pain intensity.

Anesthesia
----------

Anesthesia was accomplished along with the same standard protocol in all three groups. After the patient arrived in the operating room, premedication was done with 0.1 mg of glycopyrrolate administered intravenously. All patients were applied with noninvasive arterial blood pressure monitoring device for mean blood pressure (MBP) measurement, electrocardiogram (ECG) for heart rate (HR) monitoring, oxygen saturation (SpO~2~) measurement device, and bispectral index (BIS) monitor (Aspect A-2000^®^; Aspect Medical System Inc., Newton, MA, USA). Anesthesia was induced with 1.5 mg/kg of propofol, 0.5 μg/kg of remifentanil, and 1.2 mg/kg of rocuronium. Thereafter, mechanical ventilation was kept to maintain the end-tidal carbon dioxide at 30-40 mm Hg in 50% O~2~/air throughout the surgery. Anesthesia was maintained with 0.6-1.2 age-adjusted minimal alveolar concentration end-tidal sevoflurane and 0.02-0.2 µg/kg/min of remifentanil, which were adjusted according to stable hemodynamic variables, including MBP or HR maintained within 20% of the baseline and BIS scores between 40 and 60. Hypotension \[MBP \<60 mm Hg or systolic blood pressure (SBP) \<90 mm Hg\] was managed with fluid loading at 100 mL increments or intravenous ephedrine at 4 mg increments, and 0.25 mg intravenous atropine was used to manage bradycardia (HR \<40 beats/min). For the prevention of postoperative nausea and vomiting (PONV), 0.3 mg of ramosetron was administered at the start of peritoneal closure, and naloxone and oxygen were prepared for the event of respiratory depression. In case of the development of persistent complications such as severe PONV, hypotension, bradycardia, and respiratory depression despite of appropriate treatment, applications with the PCA machine were discontinued.

Data Collection
---------------

When the patients were transferred to the postanesthesia care unit (PACU) after surgery, they were reinstructed about the use of the PCA machine. Thereafter, recovery nurses who were not involved in this study assessed the resting NRS scores at 0.5 h and encouraged the patients to push the bolus button whenever they feel pain at a resting NRS score of \>3. For patients who showed poor response to the PCA, thus felt sustained pain at a resting NRS score of \>4, additional rescue analgesics with pethidine at 12.5 mg increments were given. After PACU discharge, postoperative pain assessment was performed at 1, 2, 3, 6, 12, 18, 24, and 36 h after surgery by the attending nurses of the Postoperative PCA Management Services of our institution, who were not aware of the purpose of this study. Similarly, for patients who experienced sustained pain at a resting NRS score of \>4 in the admission room, additional rescue analgesics of pethidine at 12.5 mg increments were also administered. After finishing the infusion of PCA, the machine was taken off and sent to the anesthesiology department for the evaluation of all records in relation to the deliveries and attempts with the bolus button. In addition to the records of the PCA machine, the number of patients who required additional rescue analgesics was also noted. MBP and HR data were collected at baseline; at PACU arrival; and at 0.5, 1, 2, 3, 6, 12, 18, 24, and 36 h after surgery. The level of sedation (assessed on a 5-point scale---0, fully awake; 1, drowsy/closed eyes; 2, asleep/easily aroused with light tactile stimulation or a simple verbal command; 3, asleep/arousable only with strong physical stimulation; and 4, unarousable) was assessed as well.

Statistical Analysis
--------------------

On the basis of a preliminary study, the mean ± standard deviation (SD) of the resting NRS score at 3 h after surgery in the IV-PCA group was 5.35, and the corresponding value for the E-PCA group was 4.38. In order to detect an expected difference of 1 with a SD of 1.8 for the resting NRS score in the dIV-PCA, the obtained sample size in each group was 51 patients with α = 0.05 and β = 0.8. Assuming a possible dropout rate of 10%, 57 patients were determined to be required in each group.

Statistical analyses were performed by using SAS software version 9.2 (SAS Inc., Cary, NC, USA) and IBM SPSS Statistics 20 (SPSS Inc., Chicago, IL, USA). All values were shown as mean ± SD, number of patients (proportion), or median (range). One-way analysis of variance was performed to analyze all parametric variables among the three groups, and nonparametric data were analyzed by using the Kruskal-Wallis test. For categorical data, the Chi-square test or Fisher\'s exact test was used in the analysis when applicable. A linear mixed model was used in the analysis for repeated-measure variables such as NRS, MBP, and HR. Post-hoc analyses with Bonferroni correction were applied when the interaction of group, time, and group by time showed statistical significance. A *P* value of \<0.05 was taken to indicate statistical significance.

Results
=======

Of 190 patients evaluated for eligibility, 171 patients were initially registered and assigned into the 3 groups. Ten patients in the E-PCA group were eliminated because PCA was discontinued owing to persistent hypotension. In the dIV-PCA group, 3 patients were excluded from the analysis for the following reasons: one patient did not receive the allocated intervention because of another surgery, one patient discontinued PCA because of persistent dizziness, and one patient had deleted PCA data due to a mechanical problem of the PCA machine. Five patients in the IV-PCA group were removed from the analysis for the following reasons: one patient did not receive the allocated intervention because of another surgery, three patients discontinued PCA because of persistent nausea, and one patient had deleted PCA data due to a mechanical problem of the PCA machine. The remaining 153 patients successfully completed the study without any complications (Figure [1](#F1){ref-type="fig"}).

The demographic and intraoperative variables were shown (Table [1](#T1){ref-type="table"}). Apart from the total administered dose of remifentanil and ephedrine, there were no significant differences among the 3 groups. The total administered dose of remifentanil was higher in the IV-PCA group than in the E-PCA and dIV-PCA groups (Bonferroni corrected *P* = 0.017 and *P* \< 0.001, respectively). In addition, the patients in the E-PCA group required more ephedrine than those in the IV-PCA group (8.4 ± 9.1 vs. 4.0 ± 4.8 μg; Bonferroni corrected *P* = 0.013).

The pain scores at rest were shown in Figure [2](#F2){ref-type="fig"}. Postoperative pain intensity was significantly lower in the dIV-PCA and E-PCA groups than in the IV-PCA group, however, it was comparable between the dIV-PCA group and the E-PCA group. After post-hoc analysis with Bonferroni corrections, the NRS scores for resting pain in the dIV-PCA group were lower than those in the IV-PCA group at all time points during the 36 h after surgery (*P* \< 0.01, Bonferroni corrected), and the E-PCA group showed lower NSR scores than those in the IV-PCA group at 0.5, 2, 3, 6, 12, 18, 24, and 36 h after surgery (*P*\< 0.01, Bonferroni corrected). Moreover, patients of the dIV-PCA group required significantly fewer additional analgesic rescues than did patients of the IV-PCA group between 2 and 24 h after surgery, and patients in the E-PCA group needed significantly fewer additional analgesic rescues than those in the IV-PCA group between 6 and 24 h after surgery (Table [2](#T2){ref-type="table"}). Figure [3](#F3){ref-type="fig"} showed the number of bolus attempts and the number of successful bolus deliveries during the first 36 h after surgery. Patients in the dIV-PCA and E-PCA groups had a significantly lower number of bolus attempts and bolus deliveries than those in the IV-PCA group during the first 24 h after surgery (both*P*\< 0.05, Bonferroni corrected).

Significant differences in MBP and HR were observed among groups in the linear mixed model analysis (*P* = 0.007 and *P* \< 0.001, respectively) (Figure [4](#F4){ref-type="fig"}). MBP in the E-PCA group was lower than that in the IV-PCA group at 3, 12, and 18 h after surgery, although more ephedrine was administered in the E-PCA group than in the IV-PCA group (*P*= 0.023, 0.010, and 0.033, respectively; Bonferroni corrected). Furthermore, patients in the dIV-PCA group showed lower MBP than those in the IV-PCA group at 1, 3, 6, 12, 18, 24, and 36 h after surgery (*P*\< 0.05, Bonferroni corrected). HR was lower in the dIV-PCA group than in the E-PCA group at 2, 3, and 6 h after surgery (*P =* 0.02, 0.01, and 0.02, respectively; Bonferroni corrected). However, no patient in either group required atropine administration. The other postoperative adverse effects were not significantly different among the 3 groups (*P*\> 0.05; Table [3](#T3){ref-type="table"}). In addition, there were no patients who exhibited respiratory depression.

Discussion
==========

This prospective randomized study demonstrated that for patients undergoing open gastrectomy, dexmedetomidine in combination with fentanyl-based IV-PCA significantly improved postoperative analgesia than fentanyl-based IV-PCA, which was comparable to thoracic E-PCA. Furthermore, such improved effects could be achieved without hemodynamic instability by using this dexmedetomidine-fentanyl combination as a noninvasive treatment.

It is generally recognized that intense pain occurring during the postoperative period may have a major impact on the postoperative clinical outcomes. Insufficient analgesia might cause psychological distress as well as physical impairment, several postoperative complications, and even progression to chronic pain [@B2], [@B26]. Especially, pain after the major abdominal surgery such as open gastrectomy could lead to restriction of thoracic and abdominal respiration as well as attenuation of vital capacity and tidal volume breathing, which probably have adverse effects on the respiratory drive [@B27], [@B28]. In addition, it may result in significant cardiovascular changes, cognitive impairment, delayed recovery of bowel motility, and neuroendocrine instability, which will most likely have a deleterious effect on the postoperative recovery process [@B4]. Thus, postoperative pain management concomitant with maintenance of hemodynamic stability is very crucial.

In the last few decades, thoracic E-PCA and IV-PCA have been generally used for postoperative analgesia in patients after open gastrectomy [@B1], [@B4]. Several studies have reported that thoracic E-PCA is considered more effective than IV-PCA in relieving postoperative pain [@B4], [@B29], [@B30]. Furthermore, current research indicates that thoracic E-PCA is considered the "golden" standard in the management of pain after the major upper abdominal surgery, owing to its excellent analgesic effects [@B1], [@B5]-[@B7]. However, it is a relatively invasive technique and its application is limited by specific contraindications such as infection or bleeding tendency [@B7]. In addition to these limitations, there is a possibility of several complications such as hematoma, or severe postoperative neurologic deficits resulting from malpositioning of the catheter in the spinal nerve roots [@B8], [@B9]. Therefore, despite its potential benefits, the clinical use of E-PCA may have even declined because of these types of complications [@B1], [@B11].

IV-PCA requires a higher dose of opioids in order to acquire satisfactory analgesic effects. This, in turn, produces adverse effects such as nausea, vomiting and pruritus, which causes patients to discontinue the use of intravenous PCA [@B1], [@B12], [@B13]. Indeed, in the present study, 3 patients in the IV-PCA group chose to discontinue the use of PCA because of persistent PONV. For postoperative recovery, it is very crucial to amplify pain relief without increasing the adverse effects of analgesics. The multimodal analgesic approach, which involves using analgesics with different action mechanisms, might be a good strategy in the current setting [@B31], [@B32]. Of the various available multimodal protocols, the combination of an opioid with one or more adjunctive drugs, such as nonsteroidal anti-inflammatory agents, pure opioid antagonists, and ketamine, has been considered the expedient option for IV-PCA in current postoperative pain management [@B33]-[@B35].

Dexmedetomidine, an extremely selective α~2~-adrenergic agonist that has hypnotic, sedative, and analgesic actions and generates sympatholytic responses, does not cause unfavorable respiratory suppression [@B14]-[@B16]. Currently, it has been suggested that combination treatment with dexmedetomidine and opioid-based IV-PCA could provide better analgesic and opioid-sparing effects without any remarkable detrimental influences [@B21]-[@B24]. However, to the best of our knowledge, no prior studies have investigated the impact of dexmedetomidine in combination with fentanyl-based IV-PCA on the attenuation of postoperative pain intensity in comparison with thoracic E-PCA and IV-PCA.

In the present study, we found significantly reduced resting NRS scores in the dIV-PCA group compared with those in the IV-PCA group during the first 36 h after surgery, although the number of bolus deliveries and attempts was significantly lower in the dIV-PCA group than in the IV-PCA group for the first 24 h after surgery; this finding was in accordance with those of previous reports [@B21]-[@B24]. Moreover, patients in the dIV-PCA group required significantly fewer additional rescue analgesics during 2-6, 6-12, and 12-24 h after surgery than those in the IV-PCA group (\**P* = 0.004, *P* \< 0.001, *P* \< 0.001, respectively; Bonferroni corrected). In the dIV-PCA group in comparison with the E-PCA group, comparable analgesic effects were achieved. A tendency was shown that the number of bolus deliveries and attempts were lower in patients of the E-PCA group than those in patients of the dIV-PCA group; however, no statistical difference was observed after post-hoc analysis with Bonferroni correction.

Epidural-induced hypotension is also very common, which is partly due to cardio-depressant activity and arteriovenous vasodilation [@B7], [@B36], [@B37]. In the present study, persistent hypotension (SBP \<90 mm Hg) developed in 10 patients of the E-PCA group. Consequently, these patients were excluded because of the discontinuation of use of the PCA machine (Figure [1](#F1){ref-type="fig"}). Except for the 10 patients who were dropped from the E-PCA group, none of the patients in all groups developed severe hemodynamic instability (SBP \<90 mm Hg, MBP \<60 mm Hg). Previous trials have been conducted with various dosages for an infusion rate of dexmedetomidine in PCA mixture from 0.02 to 0.6 µg/kg/ h within the range of the recommended dose by the manufacturer (0.2-0.7 µg/kg/ h) [@B21]-[@B24], [@B38]. In the present study, we selected 0.07 µg/kg/ h as the infusion dose and 0.007µg/kg/ h as the bolus dose with a maximum limit of 0.1µg/kg/ h in order to acquire the postoperative analgesic effect concomitant with maintaining hemodynamic stability. MBP in the dIV-PCA group were significantly lower than those in the IV-PCA group at 1 and 3-36 h after surgery; however, at all time points, the MBP in the dIV-PCA group were \>65 mm Hg. The patient who showed the lowest MBP was in the E-PCA group, which was 61 mmHg. Furthermore, 4 patients in the E-PCA group and 3 patients in the dIV-PCA group developed intermittent mild hypotension (SBP \<100 mm Hg), with no statistical difference. Moreover, no bradycardia (HR \<40 beats/min) that had to be treated with atropine occurred in all of the 3 groups. Thus, these study findings may have clinical implication, considering that low dose of dexmedetomidine-fentanyl combination significantly improved postoperative analgesia while maintaining stable hemodynamics; especially for those patients who have limitations in applying the E-PCA.

In addition, no significant difference was detected in postoperative adverse effects among the 3 groups (*P* \> 0.05). The incidence of PONV in our trials was not consistent with the findings of previous reports [@B21], [@B38]. This discrepancy might be derived from the low doses of dexmedetomidine (infusion rate, 0.07 µg/kg/ h; bolus rate, 0.007 µg/kg/ h; maximum limit, 0.1 µg/kg/ h) used in this study. Moreover, it might also be attributed to the removal of 3 patients from the IV-PCA group because of persistent PONV.

This study has several limitations. First, the patients received three different PCA regimens via different routes in accordance with the group allocation. However, we did not control this confounding factor because the objective of our study was to investigate the effect of dexmedetomidine in combination with IV-PCA on pain intensity compared with the standard methods and regimens of PCA. Second, it still needs to be clarified whether the effects of dexmedetomidine in combination with IV-PCA on pain attenuation, compared with those of E-PCA, are dose dependent. In addition, more long-term follow-up data are required to evaluate the effects of dexmedetomidine-opioid combination on postoperative outcomes, including chronic pain. Thus, further investigations are imperative. Third, we included patients with a wide age range (20 to 65 years), who underwent two types of surgeries (subtotal or total gastrectomy). Although the extent of postoperative pain intensity varies depending on the age, sex, and type of surgeries, the similar demographic variables among the 3 groups in the present study may have helped in preventing these variables from affecting the results of this study. Finally, it is uncertain whether the effects of dexmedetomidine on the attenuation of pain intensity were due to analgesic effect of itself or an indirect effect that decrease the remifentanil-induced hyperalgesia by reducing intraoperative remifentanil amounts. Therefore, more studies performed in regard to various setting would be needed.

Conclusions
===========

Dexmedetomidine in combination with fentanyl-based IV-PCA significantly improved postoperative analgesia in patients undergoing open gastrectomy than fentanyl-based IV-PCA alone, comparable to thoracic E-PCA. Such improved effects could be achieved without hemodynamic instability; furthermore, this approach could be clinically more meaningful owing to its noninvasive nature.
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![**Consort flow diagram.**E-PCA, epidural patient-controlled analgesia; dIV-PCA, dexmedetomidine in combination with fentanyl-based intravenous patient-controlled analgesia; IV-PCA, intravenous patient-controlled analgesia; SBP, systolic blood pressure; PONV, postoperative nausea and vomiting.](ijmsv14p0951g001){#F1}

![**Pain score at rest during the first 36 h after surgery.**Data are expressed as mean ± standard deviation. ^†^*P*\< 0.001, ^††^*P*\< 0.01 vs. the IV-PCA group (Bonferroni corrected); \**P*\< 0.001, \*\**P*\< 0.01 vs. the IV-PCA group (Bonferroni corrected). E-PCA, epidural patient-controlled analgesia; dIV-PCA, dexmedetomidine in combination with fentanyl-based intravenous patient-controlled analgesia; IV-PCA, intravenous patient-controlled analgesia; NRS, numerical rating scale.](ijmsv14p0951g002){#F2}

![**Number of bolus deliveries (A) and the number of bolus attempts (B) during the first 36 h after surgery.** Data are expressed as mean ± standard deviation. ^†^*P*\< 0.01, ^††^*P*\< 0.05 vs. the IV-PCA group (Bonferroni corrected); \**P*\< 0.01, \*\**P*\< 0.05 vs. the IV-PCA group (Bonferroni corrected). E-PCA, epidural patient-controlled analgesia; dIV-PCA, dexmedetomidine in combination with fentanyl-based intravenous patient-controlled analgesia; IV-PCA, intravenous patient-controlled analgesia](ijmsv14p0951g003){#F3}

![**Mean blood pressure (A) and heart rate (B) from prior induction until 36 h after surgery.**Data are expressed as mean ± standard deviation. \**P*\< 0.05, ^†^*P*\< 0.05 vs. the IV-PCA group (Bonferroni corrected); ^‡^*P*\< 0.05 vs. the E-PCA group (Bonferroni corrected). E-PCA, epidural patient-controlled analgesia; dIV-PCA, dexmedetomidine in combination with fentanyl-based intravenous patient-controlled analgesia; IV-PCA, intravenous patient-controlled analgesia; Baseline, before induction of anesthesia; PACU, on arrival of post-anesthetic care unit.](ijmsv14p0951g004){#F4}

###### 

Number of Patients Who Needed Additional Rescue Analgesics (Pethidine) During 36 h After Surgery

  ----------------------------------------------------------------------
  Interval    E-PCA group\   dIV-PCA group\   IV- PCA group\   P value
              (n = 47)       (n = 54)         (n = 52)         
  ----------- -------------- ---------------- ---------------- ---------
  0 - 2 h     16 (34%)       22 (41%)         28 (54%)         0.054

  2 - 6 h     12 (26%)       10 (19%)^\*^     23(44%)          0.012

  6 - 12 h    9 (19%)^†^     8 (15%)^\*^      24(46%)          \<0.001

  12 - 24 h   12 (26%)^†^    12 (22%)^\*^     33(63%)          \<0.001

  24 - 36 h   6 (13%)        4 (7%)           10 (19%)         0.199
  ----------------------------------------------------------------------

Data are presented as number of patients (proportion).

^†^ P \<0.01, vs. IV-PCA group (Bonferroni corrected), ^\*^ P \<0.01 vs. IV-PCA group (Bonferroni corrected)

###### 

Postoperative Adverse Effects

  ----------------------------------------------------------------
                        E-PCA\     dIV-PCA\   IV- PCA\   P value
                        (n = 47)   (n = 54)   (n = 52)   
  --------------------- ---------- ---------- ---------- ---------
  Sedation scores       0(0-0)     0(0-1)     0(0-1)     0.41

  Nausea                5          6          7          0.904

  Dizziness             1          4          3          0.594

  Headache              1          3          2          0.056

  Hypotensive episode   4          3          1          0.354

  Urinary retention     7          5          5          0.653
  ----------------------------------------------------------------

Data are presented as median (interquartile range) or number of patients. Level of sedation; 0 = fully awake, 1= drowsy/closed eyes, 2 = asleep/easily aroused with light tactile stimulation or a simple verbal command, 3 = asleep/arousable only by strong physical stimulation, and 4 = unarousable.

###### 

Patient Characteristics and Intraoperative Variables

  --------------------------------------------------------------------------------------------------
                                          E-PCA group\   dIV-PCA group\   IV- PCA group\   P value
                                          (n = 47)       (n = 54)         (n = 52)         
  --------------------------------------- -------------- ---------------- ---------------- ---------
  Age, years                              58 ± 12        59 ± 7           62 ± 13          0.148

  Height, cm                              167 ± 9        164 ± 8          163 ± 8          0.110

  Weight, kg                              64 ± 11        62 ± 9           61 ± 12          0.558

  ASA physical status, I/II               18/29          23/31            20/32            0.895

  Hypertension                            17 (36%)       19 (35%)         20 (39%)         0.955

  Diabetes mellitus                       3 (6%)         5 (9%)           6 (12%)          0.686

  Female gender                           16 (34%)       20 (37%)         20 (39%)         0.892

  Subtotal/Total                          32/15          36/18            35/17            1.000

  Duration of surgery, min                179 ± 41       170 ± 32         178 ± 43         0.500

  Fluid intake, mL                        1743 ± 468     1717 ± 489       1795 ± 744       0.783

  Blood loss, mL                          223 ± 145      213 ± 182        231 ± 166        0.859

  Urine output, mL                        241 ± 118      238 ± 171        276 ± 198        0.450

  Administered dose of remifentanil, μg   814 ± 280^†^   660 ± 260^\*^    1000 ± 400       \<0.001

  Administered dose of ephedrine, mg      8.4 ± 9.1^‡^   6.3 ± 7.5        4.0 ± 4.8        0.016
  --------------------------------------------------------------------------------------------------

Data are presented as mean ± standard deviation or number of patients (proportion). ASA = American Society of Anesthesiologist, Subtotal = subtotal gastrectomy, Total = total gastrectomy.

^†^P = 0.017, vs. IV-PCA group (Bonferroni corrected), ^\*^P \<0.001, vs. IV-PCA group (Bonferroni corrected), ^‡^P = 0.013, vs. IV-PCA group (Bonferroni corrected).
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